These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18611117)

  • 1. Tamsulosin modified release and oral controlled absorption system in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Schulman CC
    Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):771-82. PubMed ID: 18611117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamsulosin MR and OCAS (modified release and oral controlled absorption system): current therapeutic uses.
    Nargund VH; Grey AD
    Expert Opin Pharmacother; 2008 Apr; 9(5):813-24. PubMed ID: 18345957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness of Omnic and Omnic Ocas in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (multi-center observing program)].
    Shalekenov BU; Kuandykov YA; Shalekenov SB
    Urologiia; 2017 Oct; (5):42-47. PubMed ID: 29135141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study.
    Lojanapiwat B; Permpongkosol S
    Int Braz J Urol; 2011; 37(4):468-76. PubMed ID: 21888698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
    Chapple CR; Wyndaele JJ; Nordling J; Boeminghaus F; Ypma AF; Abrams P
    Eur Urol; 1996; 29(2):155-67. PubMed ID: 8647141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group.
    Abrams P; Schulman CC; Vaage S
    Br J Urol; 1995 Sep; 76(3):325-36. PubMed ID: 7551841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch from phytotherapy to tamsulosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).
    Gross AJ; Busse M; Leonard J; Schumacher H
    Prostate Cancer Prostatic Dis; 2005; 8(3):210-4. PubMed ID: 15883586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
    Schulman CC; Cortvriend J; Jonas U; Lock TM; Vaage S; Speakman MJ
    Eur Urol; 1996; 29(2):145-54. PubMed ID: 8647140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment.
    Schulman CC
    Urology; 2003 Sep; 62(3 Suppl 1):24-33. PubMed ID: 12957197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Mac Donald R; Rutks I
    Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin.
    Yang PS; Chen CL; Hou CP; Lin YH; Tsui KH
    Clin Interv Aging; 2018; 13():235-242. PubMed ID: 29445269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group.
    Chapple CR; Baert L; Thind P; Höfner K; Khoe GS; Spångberg A
    Eur Urol; 1997; 32(4):462-70. PubMed ID: 9412807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia.
    Nickel JC
    Urology; 2003 Sep; 62(3 Suppl 1):34-41. PubMed ID: 12957198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.
    Narayan P; Lepor H
    Urology; 2001 Mar; 57(3):466-70. PubMed ID: 11248621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S
    Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group.
    Schulman CC; Cortvriend J; Jonas U; Lock TM; Vaage S; Speakman MJ
    Eur Urol; 1999 Dec; 36(6):609-20. PubMed ID: 10559616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations.
    Franco-Salinas G; de la Rosette JJ; Michel MC
    Clin Pharmacokinet; 2010 Mar; 49(3):177-88. PubMed ID: 20170206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.